## REVIEWER A — Domain Expert

This is a well-structured commissioning proposal that systematically addresses the technical challenges of integrating an AI agent with an automated microscopy platform. The prerequisite integrated demonstration on static beads provides credible preliminary data, and the risk mitigations (safety watchdog, three operating modes, fallback controller, loaner agreement for the critical stage) are thorough. The scope is appropriately limited to *Elodea* chloroplasts and photobleaching, avoiding overclaiming biological discovery. The validation plan with quantified success criteria, progressive milestones, and a mid-project go/no-go review demonstrates rigorous experimental design. Minor concerns: the team relies heavily on part-time consultants and an intern, which may strain execution; also, the AI agent’s performance on dynamic moving samples remains unvalidated, though the fallback rule-based controller mitigates this risk. Overall, this is a credible, low-cost de-risking effort that directly enables a larger funded project.

| Criterion | Score |
|-----------|-------|
| Impact | 3 |
| Approach | 4 |
| Innovation | 3 |
| Preliminary Data | 4 |
| PI & Team | 3 |
| Feasibility | 4 |
| Experimental Design | 4 |
| Budget | 4 |
| Clarity | 4 |
| Ethics | 5 |
| Overall | 4 |

**Score Sum: 42/55**

---

## REVIEWER B — Fluff/Impact Auditor

The proposal clearly articulates its value: a $4,200 investment protecting an $80k–$200k downstream experiment, with a quantified 15–25% risk reduction. The impact narrative is grounded and not overhyped. The document avoids fluff by explicitly listing what is *not* validated and by framing stretch goals (7-day uptime) as secondary. Budget is tight but justified, and the contingency is conservatively allocated to low-cost parts with a loaner agreement covering the critical component. However, the “vision” section still reads as slightly self-congratulatory, and the connection to “LongevityCommon” repositories is vague (no metrics of community adoption). The team section lacks demonstration of prior successful system integrations; the PI’s CV is not provided. The preliminary data (static bead demo) is appropriate for a commissioning project, but for impact auditing, I would have liked a clearer cost–benefit calculation (e.g., expected cost of failures avoided vs. cost of Phase 0). Overall, a lean, honest proposal that could benefit from sharper quantification of risk reduction.

| Criterion | Score |
|-----------|-------|
| Impact | 4 |
| Approach | 3 |
| Innovation | 2 |
| Preliminary Data | 3 |
| PI & Team | 2 |
| Feasibility | 3 |
| Experimental Design | 3 |
| Budget | 5 |
| Clarity | 4 |
| Ethics | 5 |
| Overall | 3 |

**Score Sum: 37/55**

---

## REVIEWER C — Red Team

This is a well-intentioned proposal but remains insufficiently de-risked for the stated goals. The only integrated demonstration was on static, immobile beads; the AI agent’s performance on dynamic *Elodea* chloroplasts—the actual testbed—is entirely unknown. The validation plan schedules dynamic tracking for M3, yet the go/no-go decision at M2 only applies to static samples, meaning the largest risk (agent failure on moving targets) is not addressed until late in the project. The team lacks a published track record in either microscopy automation or AI-agent control; the PI is a solo lead with part-time consultants, and the intern’s 15 hrs/week will barely cover routine testing. The safety watchdog validation (100% detection over 500 injections) is impressive but tested only on *injected* unsafe commands, not on actual agent-generated hallucinations—a critical gap. Budget is low, but 10% contingency is inadequate for a novel system integration where even minor component failures (e.g., camera cable failure) can cause weeks of delay. The impact on “LongevityCommon” ecosystems is aspirational, not evidence-based. For a pure commissioning project, the success criteria (≥90% uptime, precision >0.9) are ambitious given the lack of dynamic sample data. Major revisions are required, including a preliminary dynamic sample test, a more robust team plan, and a higher contingency.

| Criterion | Score |
|-----------|-------|
| Impact | 2 |
| Approach | 3 |
| Innovation | 2 |
| Preliminary Data | 2 |
| PI & Team | 2 |
| Feasibility | 3 |
| Experimental Design | 3 |
| Budget | 4 |
| Clarity | 4 |
| Ethics | 4 |
| Overall | 2 |

**Score Sum: 31/55**

---

## Combined Verdict

**Combined Score: MIN = 31/55**

**Recommendation:** Major Revisions

**Top 3 Actions:**
1. **Demonstrate AI agent performance on dynamic *Elodea* chloroplasts (even a short 10-minute run) before final approval.** This is the single highest-risk unknown; a preliminary proof on moving targets would transform reviewer confidence.
2. **Strengthen the team and contingency.** Provide evidence of the PI’s prior successful system integrations (e.g., a link to a previous automated build) or add a co-PI with a proven track record in robotics/AI. Increase contingency from 10% to at least 20% (or clearly justify why a single loaner agreement covers all critical-path failures).
3. **Add an independent validation step for the AI agent’s decision-making on real, dynamic tasks.** For example, a blinded human evaluation of 100 agent decisions on logged live-sample video frames, with a formal inter-rater reliability metric. This would address the red team’s concern about hallucination risk beyond safety-injection testing.